Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

Delayed Quote. Delayed Nasdaq - 07/30 04:00:02 pm
322.18 USD   +5.80%
5h agoDJBioMarin Sells Priority Review Voucher To Regeneron
11h ago S&P 500 MOVERS : Gnw, ew
11h ago NASDAQ 100 MOVERS : Grmn, regn
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/24/2014 07/25/2014 07/28/2014 07/29/2014 07/30/2014 Date
304.44(c) 303.09(c) 302.16(c) 304.51(c) 322.18(c) Last
605 549 369 087 532 188 303 028 2 372 930 Volume
-1.88% -0.44% -0.31% +0.78% +5.80% Change
More quotes
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and... 
Sector
Pharmaceuticals
Calendar
08/05Earnings Release
Surperformance© rating of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More about the company
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 2 748 M
EBIT 2014 1 126 M
Net income 2014 445 M
Finance 2014 1 133 M
Yield 2014 -
Sales 2015 3 410 M
EBIT 2015 1 497 M
Net income 2015 769 M
Finance 2015 2 307 M
Yield 2015 -
PER 2014 79,51
PER 2015 46,73
EV / Sales 2014 10,8x
EV / Sales 2015 8,33x
Capitalization 30 719 M
More Financials
Latest news on REGENERON PHARMACEUTICALS
5h agoDJBioMarin Sells Priority Review Voucher To Regeneron
11h ago S&P 500 MOVERS : Gnw, ew
11h ago NASDAQ 100 MOVERS : Grmn, regn
14h ago REGENERON PHARMACEUTICALS : EYLEA® (aflibercept) Injection Receives FDA Approval..
15h agoDJSANOFI : Regeneron's Alirocumab Shows Promise in Phase III Trials
19h agoDJBAYER : FDA Approves Bayer's Eylea for Diabetic Macular Edema Treatment
21h ago REGENERON PHARMACEUTICALS : Sets Date for Release of Q2 2014 Financial Results
07/23 REGENERON PHARMACEUTICALS : Two-Year Results From Phase 3 VIVID-DME Trial of EYL..
07/23 REGENERON PHARMACEUTICALS : Schedules Release of Q2 2014 Financial Results
07/18 REGENERON PHARMACEUTICALS : and Sanofi Report Dupilumab Study Results
07/18 REGENERON PHARMACEUTICALS : to Report Second Quarter 2014 Financial and Operatin..
07/18 REGENERON PHARMACEUTICALS : Two-Year Results From Phase 3 VIVID-DME Trial of EYL..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
Regeneron Pharmaceuticals  : Income Statement Evolution
More Financials
EPS Revisions
Regeneron Pharmaceuticals  : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF